# VRTX earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/VRTX) · [Earnings tab](https://www.lopjlb.com/stock/VRTX?tab=earnings)

Updated: 2026-08-03T03:00:48

Quarters analyzed: 8

## Cross-quarter narrative

Across the eight earnings calls, Vertex moved from modest revenue reporting in early 2024 to a clear trajectory of double‑digit growth and expanding product breadth by mid‑2026. Initial calls highlighted steady revenue (~$2.6‑$2.8B) and the rollout of CASGEVY, while Q4 2024 introduced two new launches (ALYFTREK, JOURNAVX) and a leadership transition. The Q2 2025 call emphasized continued 12% YoY growth driven by those launches, a sizable cash position, and a shift toward aggressive share‑repurchase programs alongside innovation spending. That quarter also surfaced the first major setbacks – the VX‑993 acute‑pain trial failure and emerging regulatory doubts around suzetrigine’s label. By Q4 2026, growth moderated to high‑single‑digit rates, gross margins rose to ~86%, and the pipeline showed deeper progress in cystic fibrosis, renal and autoimmune areas, with new products (Kasjevi, Gernavix) contributing to revenue. Concerns evolved from early regulatory and efficacy risks to safety (hypogammaglobulinemia with povetacicept), reimbursement timing, and competitive pressures in myasthenia gravis. Throughout, guidance remained broadly maintained, while the company’s capital strategy increasingly blended buybacks with continued pipeline investment.

## Latest CallCard · Q1

Vertex Q1 2026: $2.99B revenue (+8% YoY), CF growth 6%, new products (Kasjevi, Gernavix) drive 25% of growth; Povi IgAN Phase III 'sparkling' results, BLA filed in record 27 days; guidance maintained $12.95-13.10B. VX-522 discontinued. Zamylosel dosing resumed. Renal franchise advancing rapidly. Gro

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q1:** Vertex Q1 2026: $2.99B revenue (+8% YoY), CF growth 6%, new products (Kasjevi, Gernavix) drive 25% of growth; Povi IgAN Phase III 'sparkling' results, BLA filed in record 27 days; guidance maintained $12.95-13.10B. VX-522 discontinued. Zamylosel dosing resumed. Renal franchise advancing rapidly. Gro
- **2025 Q4:** Vertex reported 10% Q4 revenue growth, 9% FY growth, strong CF and renal pipeline progress, and 2026 revenue guidance of $12.95‑$13.1B with non‑CF contribution of $500M+.
- **2025 Q3:** —
- **2025 Q2:** VRTX Q2 revenue $2.96B (+12% YoY) driven by ALYFTREK, JOURNAVX, CASGEVY launches; pipeline advances with povetacicept, inaxaplin, zimislecel; guidance maintained; VX-993 acute pain monotherapy halted.
- **2025 Q1:** —
- **2024 Q4:** Vertex delivered strong Q4/FY2024 results ($11B revenue, +12%), launched ALYFTREK and JOURNAVX, advanced CASGEVY globally, and guided 2025 revenue $11.75-12B (+8%) with pipeline milestones in diabetes, renal, and pain. Leadership transition: Stuart Arbuckle retiring July 1, Charlie Wagner adds COO, 
- **2024 Q3:** Vertex Q3 revenue $2.77B (+12% YoY), raised FY guidance to $10.8-10.9B; CASGEVY launch progressing with first commercial dose; vanzacaftor triple and suzetrigine PDUFA dates early 2025; multiple Phase 3 programs advancing.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Prepared remarks emphasize strong m
- **2024 Q2:** Vertex Q2 revenue $2.65B

## Theme arcs

- **Revenue growth** (improving): From $2.65B in Q2 2024 to $2.99B in Q1 2026 with consistent double‑digit YoY increases, later moderating to high‑single‑digit growth.
- **Product launch momentum** (improving): Launches progressed from CASGEVY to ALYFTREK, JOURNAVX, Kasjevi and Gernavix, expanding the portfolio.
- **Pipeline advancement** (improving): Multiple Phase III and Phase I studies moved on‑track, with new renal and autoimmune candidates advancing.
- **Guidance consistency** (stable): Revenue guidance was raised in 2024, then maintained through 2025‑2026.
- **Capital allocation** (improving): Cash balance grew to $12B, share‑repurchase activity intensified, and a $4B buyback was authorized.
- **Margin pressure** (deteriorating): Non‑GAAP operating expenses rose 24% YoY in Q2 2025, though gross margin later improved to ~86%.
- **Management confidence** (new): Tone scores rose to 0.70 in Q2 2025 and Q4 2026, indicating stronger confidence.

## Guidance path

2024 Q2:vague → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:maintained → 2025 Q3:vague → 2025 Q4:maintained → 2026 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/VRTX`